Trial Profile
Phase 1 multicenter, dose-escalation clinical study of the safety and tolerability of intravenously administered SNS-032 injection, a novel cyclin-dependent kinase inhibitor, administered to patients with advanced B-lymphoid malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs SNS 032 (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Multiple myeloma
- Focus Adverse reactions
- Sponsors Sunesis Pharmaceuticals
- 06 Jun 2012 Actual patient number changed from 40 to 21 as reported by ClinicalTrials.gov.
- 19 May 2010 Status changed from active, no longer recruiting to completed, as results have been reported.
- 19 May 2010 Results published online in Journal of Clinical Oncology, according to a media release from the John Theurer Cancer Center.